论文部分内容阅读
目的分析聚乙二醇干扰素α-2a治疗慢性乙型肝炎的中长期疗效,为临床用药提供参考。方法将56例慢性乙肝患者分为两组各28例,治疗组予聚乙二醇干扰素α-2a180μg皮下注射,每周1次,治疗48周;对照组予普通干扰素500万U皮下注射,隔日1次,疗程48周。在治疗24、48周和随访48周时观察两组的HBV DNA应答率、HBeAg阴转率和ALT复常率。结果治疗24周时,两组HBV DNA应答率、HBeAg阴转率、ALT复常率差异不明显;治疗48周和随访48周时,治疗组HBV DNA应答率、HBeAg阴转率、ALT复常率均明显高于对照组(P<0.05)。结论聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效显著,且保持持久性应答。
Objective To analyze the long-term curative effect of peginterferon alfa-2a in the treatment of chronic hepatitis B, and to provide reference for clinical use. Methods A total of 56 patients with chronic hepatitis B were divided into two groups of 28 patients. The patients in the treatment group were injected subcutaneously with pegylated interferon alfa-2a 180μg once a week for 48 weeks. The control group was injected subcutaneously with normal interferon 5 million U , Every other day, treatment for 48 weeks. The HBV DNA response rate, HBeAg negative conversion rate and ALT normalization rate were observed at 24, 48 weeks and 48 weeks after treatment. Results After treatment for 24 weeks, there was no significant difference in HBV DNA response rate, HBeAg negative conversion rate and ALT recovery rate between the two groups. After 48 weeks of treatment and 48 weeks of follow-up, the HBV DNA response rate, HBeAg negative conversion rate and ALT normalization Rates were significantly higher than the control group (P <0.05). Conclusion Pegylated interferon α-2a treatment of chronic hepatitis B patients with significant effect, and maintain a lasting response.